Search
dexrazoxane (Zinecard, Cardioxane)
Tradename: Zinecard.
Indications:
1) reduction in the incidence & severity of cardiomyopathy associated with doxorubicin administration) women with metastatic breast cancer who have received a total dose of doxorubicin of 300 mg/m2 & would benefit from continued doxorubicin therapy
2) NOT recommended for use with initiation of doxorubicin therapy
Contraindications:
- NOT for use with chemotherapeutic regimens that do not include an anthracycline
Powder for injection: lyophilized 250 & 500 mg (10 mg/mL when reconstituted)
Monitor: complete blood count (CBC)
Adverse effects:
1) difficult to dissect from adverse effects of chemotherapeutic regimens
2) pain on injection
3) myelosuppression
a) more severe leukopenia, granulocytopenia, thrombocytopenia at nadir
b) recovery counts unaffected
4) urticaria (1-2%)
5) recall skin reaction (1-2%)
6) extravasation (1-2%)
Drug interactions:
- other myelosuppressive agents
Interactions
drug interactions
Related
doxorubicin (Adriamycin, Rubex)
General
razoxane
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Department of Veterans Affairs, VA National Formulary